Yes, thank you, Madam Chair.
We've seen nothing in the materials provided by Health Canada to suggest that the barrier is in any way going to be lowered for access to market for new drugs by adding a post-surveillance component. Health Canada has consulted as recently as February 15 with the health professions and has overtly stated that the current regulatory regime for market approval will not be changed.